Chemical formula: C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂ Molecular mass: 776.35 g/mol PubChem compound: 9854012
Cangrelor is a direct P2Y12 platelet receptor antagonist that blocks adenosine diphosphate (ADP)-induced platelet activation and aggregation in vitro and ex vivo. Cangrelor binds selectively and reversibly to the P2Y12 receptor to prevent further signalling and platelet activation.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AC25 | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AC Platelet aggregation inhibitors excl. heparin | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| KENGREXAL Powder for concentrate solution | European Medicines Agency (EU) | MPI, EU: SmPC |
Cangrelor is an active ingredient of these brands:
United States (US)Austria (AT)
Croatia (HR)
Estonia (EE)
Finland (FI)
France (FR)
Ireland (IE)
Italy (IT)
Lithuania (LT)
Netherlands (NL)
Poland (PL)
Romania (RO)
Spain (ES)
Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
